Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP1 | O94782 | 8/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314673 | 0.90 | CHRM1 (0.57) | CHRM1USP1 | |
| SCHEMBL11895623 | 0.88 | CHRM1 (0.70) | CHRM1CNR1CNR2 | |
| SCHEMBL11895310 | 0.88 | CHRM1 (0.56) | CHRM1KDM4ELMNASMN1; SMN2CNR2 | |
| SCHEMBL1666095 | 0.86 | CHRM1 (0.54) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL10277336 | 0.83 | CHRM1 (0.58) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL1666184 | 0.83 | CHRM1 (0.58) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL11894871 | 0.82 | CHRM1 (0.49) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL6900579 | 0.82 | CHRM1 (0.39) | CHRM1KDM4ECNR1CNR2TP53 | |
| SCHEMBL6898796 | 0.81 | CHRM1 (0.48) | CHRM1KDM4ELMNASMN1; SMN2USP1 | |
| SCHEMBL10277233 | 0.80 | CHRM1 (0.47) | CHRM1KDM4ELMNASMN1; SMN2USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | claimed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | claimed |
| WO-2011041143-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-07 | — | — | WO | claimed |
| EP-2483275-B1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426438-B2 | Heterocyclic-fused pyrazolo[4,3-c]pyridin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2483275-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Schering Corporation (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
| WO-2011041143-A1 | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178760-A1 | Heterocyclic-Fused Pyrazolo[4,3-c] Pyridin-3-One M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM4, CHRM2 | CHRM1 1/4885KDM4E 1642/4885LMNA 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.